Cancer Family
Peritoneal Neoplasm
CI-CAN-00000318Explore in graph →
Non-malignant142 active trials5 approved drugs2 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000318Explore in graph →
Clinical trials
592 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | terminated | Phase 3 | 1,015 | AmgenINDUSTRY | 14 | Feb 23, 2017 | clinicaltrials |
| NCT00352755 | A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis | terminated | Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Dec 13, 2016 |
| clinicaltrials |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | terminated | Phase 1 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00536523 | Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | — | 13 | University of MinnesotaOTHER | 1 | Aug 22, 2014 | clinicaltrials |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT01821859 | Abraxane/Bevacizumab | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 134 | Cancer Research UKOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00288275 | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | terminated | — | 256 | Precision TherapeuticsINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00669422 | ChemoFx® PRO - A Post-Market Data Collection Study | terminated | — | 2,756 | Precision TherapeuticsINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | 16 | Facet BiotechINDUSTRY | 2 | Aug 23, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00897806 | Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00445549 | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT01096381 | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | terminated | — | 8 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 27, 2012 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Feb 23, 2017source: clinicaltrials